undamentalytics Newsletter
Sign in

Organon & Co. balance sheet

At the end of fiscal 2025, Organon & Co. had total assets of $12.87bn, total liabilities of $12.12bn and shareholders' equity of $752m. It held $574m in cash against $8.64bn of debt: net debt of $8.07bn.

Balance sheet

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash and equivalents0.00.00.70.70.70.70.61.5
Receivables—1.01.41.51.71.41.31.5
Inventory—0.90.91.01.31.31.41.4
Total current assets—3.63.83.94.54.34.45.4
Goodwill—4.64.64.64.64.74.24.2
Total assets—10.110.711.012.113.112.913.4
Accounts payable—0.31.41.11.31.21.01.0
Total current liabilities—2.72.62.52.92.72.42.7
Short-term debt—0.00.00.00.00.00.00.1
Long-term debt—0.09.18.98.88.98.68.5
Total debt0.00.09.18.98.88.98.68.6
Total liabilities———11.812.112.612.112.2
Shareholders' equity7.05.5−1.5−0.9−0.10.50.81.2
Net debt (negative = net cash)0.0−0.08.48.28.18.28.17.1
Shares outstanding——254m254m256m258m260m263m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ELAN vs OGNJAZZ vs OGNOGN vs ZTS

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Organon & Co.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Organon & Co.